Parkinson disease (PD) begins with a long preclinical phase, which represents both a diagnostic challenge and a potential therapeutic opportunity for early intervention. Parnetti and colleagues discuss growing evidence to support the utility of cerebrospinal fluid levels of various proteins, such as α-synuclein, amyloid-β and tau, as accessible biomarkers for PD diagnosis. The authors emphasise the importance of measuring multiple biomarkers in combination to improve diagnostic accuracy.
- Lucilla Parnetti
- Anna Castrioto
- Paolo Calabresi
